European Patent Office Upholds Gilead’s Sofosbuvir Patent
Executive Summary
A challenge brought to the European Patent Office that sought to open the door to generic competition to Gilead’s hepatitis C treatment has failed.
You may also be interested in...
Sofosbuvir Patent Challenge Could Highlight Weaknesses In IP Systems
NGOs from across Europe are challenging a patent protecting Gilead’s Sovaldi in an effort to expand patient access to hepatitis C treatments. They say the case will also expose failings in the intellectual property rights system that hinder access to innovation.
Fresh EU-Wide Challenge To Sovaldi Patent Puts The Spotlight On Drug Pricing Again
Access to affordable medicines has become a global challenge. A new chapter has been added to the struggle as several EU-based civil society groups join hands to challenge Gillead’s sofosbuvir patent in a bid to increase access to affordable hepatitis C treatment.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.